GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Diaceutics DXRX.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

197.50p

-1.50%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Diaceutics

Its shares trade on LSE under the ticker DXRX.L. It has been listed since 21 March 2019. In the fiscal year to 31 December 2024, it reported revenue of £32.2m and a net loss of £1.7m. At that date it held total assets of £48.6m and shareholders' equity of £39.9m.

Diaceutics Plc provides data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The firm offers end to end services that encompasses from understanding the diagnostic landscape to test implementation into treatment pathways to enable better treatment decisions for patients. The Company’s data analytics and implementation services, including Landscape, Tracking, and Primary Market Research, leverages the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Its implementation services include Planning, Commercialization and Reimbursement Landscapes, to build the strategies and implement the tactics that drives optimal test utilization, ensuring that patients are getting the right treatment.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
21 Mar 2019
Employees
111

Leadership

Pay as last reported

  • Mr. Peter KeelingNon-Executive Chairman of the Board, since 2024£234,010
  • Mr. Ryan KeelingChief Executive Officer, Executive Director, since 2024£541,475
  • Mr. Nick RobertsChief Financial Officer, Executive Director, since 2022£387,306
  • Ms. Sandra BlakeChief People Officer
  • Ms. Lauren DewittExecutive Vice President, Legal, General Counsel, Group Company Secretary
  • Ms. Marianna SciortinoVice President - Sales
  • Ms. Amie McneiceVice President - Marketing
  • Ms. Madeline BrownVice President, Chief of Staff
  • Mr. Kerri DonaldsonVice President - Customer Operations
  • Ms. Gosia LeitchVice President - Engagement Solutions
  • Mr. Scott PhillipsVice President - Real-World Data
  • Mr. Ken RuppelVice President - Scientific and Medical Services

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Diaceutics PLC has several notable strengths which contribute to its success in the market:

Weaknesses

  • Despite its strengths, Diaceutics PLC faces certain weaknesses that may pose challenges:

Opportunities

  • Diaceutics PLC can explore the following opportunities to drive future growth:

Threats

  • Diaceutics PLC should be mindful of the following threats that could impact its business:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.